PROSCA/BLADDR 2022 | Patient and physician treatment decision-making: active surveillance or intervention

Johan Stranne, MD, PhD, Sahlgrenska University Hospital, Gothenburg, Sweden, reflects on the importance of physicians in helping decision-making for men with prostate cancer deciding between therapy or active surveillance, with the patient’s personal goals important to be held in mind. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.